17 results about "Optic neuropathy" patented technology

The present invention generally relates to compositions and methods useful for treating a brain injury such as stroke, optic neuropathy, traumatic brain injury, and cerebral palsy. The methods include administering HMCs obtained by in vitro differentiation of pluripotent stem cells and / or extracellular vesicles (EVs) derived from such HMCs (HMC-EVs) into a subject.

The present disclosure relates to nanoemulsions of 5-amino-[4-(4-chlorobenzoyl)-3,5-dichlorobenzyl]-1,2,3-triazole-4-carboxamide (carboxy-amido-triazole or CAI), methods of preparing thereof, and their use in the treatment of inflammatory optic neuropathies.

Provided are: a kit for inducing differentiation, which is for inducing the differentiation of a Muller glial cell into a retinal ganglion cell in vivo in a mammal; and a pharmaceutical composition for treating glaucoma or optic neuropathy. The kit and the pharmaceutical composition each include: a nucleic acid encoding NEUROG2; a combination of a nucleic acid encoding ASCL1, a nucleic acid encoding BRN3B, and a nucleic acid encoding ATOH7; or a combination of a nucleic acid encoding ASCL1, a nucleic acid encoding BRN3B, and a nucleic acid encoding ISL1.

The present invention relates to a base correction system that corrects mitochondrial DNA mutations G3460A, G11778A, or T14484C, which are present in patients with Leber's hereditary optic neuropathy (LHON), to a normal genotype. Specifically, the present invention provides a base editor capable of correcting a mutation site in a mitochondrial gene of an LHON patient to a normal genotype. The present invention also provides a method for correcting a mitochondrial gene mutation using a fusion protein or a polynucleotide encoding such a fusion protein that recognizes a specific site in the mitochondrial gene of an LHON patient and specifically corrects the adenine base at position 3460, the adenine base at position 11778, or the cytosine base at position 14484. The base editor or polynucleotide according to the present invention can be used in cells or in an extracellular test tube environment to correct DNA mutations specifically expressed in LHON, and more preferably, can be used as a gene therapy agent to prevent or treat the disease. Thus, the present invention also provides a use of the substance for preventing or treating Leber's hereditary optic neuropathy.

The present disclosure relates to nanoemulsions of 5-amino-[4-(4-chlorobenzoyl)-3,5-dichlorobenzyl]-1,2,3-triazole-4-carboxamide (carboxy-amido-triazole or CAI), methods of preparing thereof, and their use in the treatment of inflammatory optic neuropathies.

The present disclosure provides compositions and methods for treating a mammalian subject for an ON neuropathies and / or reducing or ameliorating degeneration of axons and / or soma of RGCs. Aspects of the composition include a neuroprotective agent and a pharmaceutically acceptable excipient, where the neuroprotective agent inhibits HRH1 activity. A variety of ON neuropathies may be treated by practicing the methods, including retinal ganglion cell degeneration, glaucoma, optic neuritis, ON traumatic injury and other ON-related diseases.

The present disclosure provides methods and uses of aminonaphthoquinone compounds in treatment and / or prevention of an optic neuropathy.

Disclosed is a method of producing ganglion progenitor cells from pluripotent stem cells and their use for treating ocular disorders. In particular, disclosed is a method of producing ganglion progenitor cells from pluripotent stem cells by transducing pluripotent stem cells with the neuronal differentiation transcription factor Neuronal Differentiation 1 (NEUROD1) in a chemically-defined and xenogenic-free culture medium and their use for treating ocular disease and / or an optic neuropathy.

The invention discloses an optic nerve image enhancement and lesion recognition method based on multi-modal fusion, and the method comprises the following steps: S1, collecting the image data of an optic nerve lesion patient, and carrying out the denoising processing, spatial position alignment and data normalization; s2, constructing an improved conditional diffusion probability model, and establishing a reverse diffusion process for image detail enhancement; s3, gradually enhancing image data details by using a reverse diffusion process; s4, calculating high-dimensional conditional probability feature joint distribution of different modal image space domains and frequency domains, and establishing a cross-modal feature set; s5, performing image adaptive fusion by adopting a conditional guidance mechanism; s6, optimizing model parameters to obtain a fused image; and S7, identifying the feature vector of the lesion area by using a Transform classification model to realize lesion identification and classification diagnosis. According to the invention, the image fusion quality and the lesion diagnosis precision are obviously improved.

The present application relates to the field of medicine, in particular to the use of a substance specifically binding to NSE protein or its encoding gene in the preparation of a diagnostic product or a prognostic product for ARN. By detecting NSE protein or its encoding gene, the optic neuropathy caused by acute retinal necrosis can be understood, and doctors can identify ARN conditions earlier, so as to promptly implement appropriate medical intervention. Therefore, the present application can not only significantly reduce the risk of retinal detachment and vision loss, but also assist clinicians in accurately assessing the severity of the disease and predicting the possibility of vision recovery, which can promote the individualization and precision of treatment. In addition, by avoiding unnecessary drug use and wasting of medical resources, it also brings economic benefits, which benefits patients and society.

The present invention provides aminonaphthoquinone compounds for the treatment and / or prevention of optic neuropathy. [Solution] This disclosure provides methods and uses of aminonaphthaquinone compounds in the treatment and / or prevention of optic neuropathy. The present invention also provides a pharmaceutically acceptable composition for use in a method for preventing and / or treating optic neuropathy associated with apoptosis of RGCs, wherein the pharmaceutically acceptable composition comprises a compound of formula (I) described herein. The use of a pharmaceutically acceptable composition in the manufacture of a pharmaceutically acceptable composition for preventing and / or treating optic neuropathy associated with apoptosis of RGCs is also provided, wherein the pharmaceutically acceptable composition comprises a compound of formula (I) described herein.

A method of treating optic neuropathy that provides surprising efficacy while minimizing toxicity using a specific administration regimen with an effective amount of a compound of Formula (I):

The application discloses a gene medicine for treating deafness-dystonia-optic neuropathy syndrome caused by TIMM8A gene defect and application. The medicine core is a modularly designed adeno-associated virus vector system which carries an expression cassette containing a tissue-specific promoter and a human TIMM8A treatment gene. The application realizes precise treatment through local minimally invasive injection according to different symptoms: AAV-Anc80L65-MYO15-TIMM8A is injected into the cochlea to treat sensorineural hearing loss; AAV2 / 4-Brn3b-TIMM8A is injected into the vitreous body of the eyeball to treat optic neuropathy; AAV9-hSyn-TIMM8A is injected into the central lateral ventricle to treat dystonia. Preclinical studies have confirmed that the strategy can efficiently express TIMM8A protein in the corresponding target cells, significantly repair hearing, visual and motor function defects, and correct mitochondrial dysfunction from the pathological mechanism.

The application belongs to the technical field of biological medicine, and discloses application of plerixafor in preparation of a medicine for treating traumatic optic neuropathy. Researches of the application show that the plerixafor has a repairing effect of promoting survival of retinal ganglion cells (RGC) and axon regeneration after optic nerve injury, and can achieve and improve the effect of treating traumatic optic nerve injury.

The present disclosure provides compositions and methods for treating a mammalian subject for an ON neuropathies and / or reducing or ameliorating degeneration of axons and / or soma of RGCs. Aspects of the composition include a neuroprotective agent and a pharmaceutically acceptable excipient, where the neuroprotective agent inhibits HRH1 activity. A variety of ON neuropathies may be treated by practicing the methods, including retinal ganglion cell degeneration, glaucoma, optic neuritis, ON traumatic injury and other ON-related diseases.

The present application relates to antibodies or anti-gen-binding fragments thereof that specifically bind to TrkB and / or CD3, and to nucleic acids encoding such antibodies or antigen-binding fragments thereof, as well as to pharmaceutical compositions comprising the antibodies, antigen-binding fragments thereof or nucleic acids. Bispecific antibodies specifically binding to TrkB and CD3 are also described. The antibodies, antigen-binding fragments thereof, nucleic acids or pharmaceutical compositions may be useful for modulating the activity of CD3 and / or TrkB-expressing cells such as neural cell and T lymphocytes, and for the treatment of diseases or conditions in which stimulation or inhibition of CD3 and / or TrkB is beneficial, such as neurodegenerative diseases, optic neuropathy and metabolic diseases, mental disorders as well as for the treatment of autoimmune disorders and cancers.

The invention discloses a biomarker for detecting high myopia complicated with optic neuropathy, a detection kit and application, and belongs to the technical field of biomedical detection. The technical problem to be solved is that a biomarker for detecting high myopia complicated with optic neuropathy is lacked in the prior art. The key point of the technical scheme is to provide application of CCN2 (Cell Communication Network Factor 2) in preparation of a reagent for detecting high myopia concurrent optic neuropathy.